Release time：Nov 08, 2024
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin? (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.
7MW4811 is developed with Mabwell’s next-generation ADC technology (IDDC?) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors.
IDDC? is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload Mtoxin? (MF6), these ADCs have been furthered optimized, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.
